Teva, Sandoz Lose Incontinence IP Appeal As Astellas Prevails
An appeals court has rejected a challenge from generic drugmakers Teva Pharmaceuticals and Sandoz AG to a ruling that a patent protecting a rival's incontinence treatment was valid, tossing contentions that...To view the full article, register now.
Already a subscriber? Click here to view full article